Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News ZyVersa Therapeutics Inc (QB) ZVSA

Healthcare Biotechnology
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental... see more

Current News (OTCQB:ZVSA)

ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results

GlobeNewswire November 19, 2025

ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes

GlobeNewswire September 10, 2025

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression

GlobeNewswire September 3, 2025

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression

GlobeNewswire August 14, 2025

ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

GlobeNewswire August 13, 2025

ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress

GlobeNewswire July 21, 2025

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds

GlobeNewswire July 8, 2025

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator(TM) VAR 200 in a Patient with ApoCII Amyloidosis

GlobeNewswire July 8, 2025

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator(TM) VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)

GlobeNewswire June 26, 2025
View More News ››

Opinion & Analysis (OTCQB:ZVSA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (OTCQB:ZVSA)

ZVSA.....trading at $1.78 this a.m

I'll say it now .....All the Chsers have been had....AGAIN !!!
Iseneschal - November 6, 2024

RE:ZVSA.....I'd say we get some "sideways action" for a awhile

Well that didn't happen ; ) The support has been broken....as I previously mentioned.....she's done Should have just kept my...
Iseneschal - November 5, 2024

ZVSA.....I'd say we get some "sideways action" for a awhile

possible bounce and vol spike If ur in ....use it to sell...currently at $2.60 JMHO
Iseneschal - November 5, 2024

ZVSA....2 x's tap on the L.O.D....

which is that support line I mentioned Better hold and rally or its done
Iseneschal - November 5, 2024

RE:ZVSA.......I have started a short position

Covered short position at $2.69 I'll take that profit any day Might re-enter the short position
Iseneschal - November 5, 2024

ZVSA.... now let's see if my calculations are correct ; )

Currently trading at ~ $2.82 I see support at $2.61 Vols are declining ....this better hold the support or it's done
Iseneschal - November 5, 2024
View more Bullboard ››

Blue Sky Uranium Corp.

Blue Sky Uranium Corp.

Blue Sky Uranium Corp., a junior uranium exploration company, engages in the acquisition, exploration, and evaluation of ...
View More »

Podcasts